Aldosterone and cardiovascular risk

Current Hypertension Reports

Volumn 11, Issue 6, 2009, Pages 450-455

  Burnier, Michel ^a   Vogt, Bruno ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; EPITHELIAL SODIUM CHANNEL; EPLERENONE; MINERALOCORTICOID; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; SPIRONOLACTONE; TORCETRAPIB; TRILOSTANE; UBIQUITIN PROTEIN LIGASE NEDD4;

ALDOSTERONE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG FATALITY; ESSENTIAL HYPERTENSION; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY DISEASE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; POTASSIUM BLOOD LEVEL; POTASSIUM METABOLISM; PRIMARY HYPERALDOSTERONISM; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; SIDE EFFECT; SODIUM BLOOD LEVEL; SODIUM METABOLISM; ST SEGMENT ELEVATION; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; HUMANS; HYPERALDOSTERONISM; KIDNEY DISEASES; METABOLIC SYNDROME X; OBESITY; QUINOLINES;

EID: 72549105303     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0076-8     Document Type: Review

References (50)

1. J.M. Connell E. Davies 2005 The new biology of aldosterone J Endocrinol 186 1 20 10.1677/joe.1.06017 1:CAS:528:DC%2BD2MXmvV2hsbY%3D 16002531 (Pubitemid 41015660)
2. B.C. Rossier S. Pradervand L. Schild, et al. 2002 Epithelial sodium channel and the control of sodium balance: interaction between genetic and environmental factors Annu Rev Physiol 64 877 897 10.1146/annurev.physiol.64. 082101.143243 1:CAS:528:DC%2BD38XisFGmtrs%3D 11826291 (Pubitemid 34259252)
3. E. Davies S.M. Mackenzie 2003 Extra-adrenal production of corticosteroids Clin Exp Pharmacol Physiol 30 437 445 10.1046/j.1440-1681.2003.03867.x 1:CAS:528:DC%2BD3sXls1KrtLs%3D 12823256 (Pubitemid 36836558)
4. E.P. Gomez-Sanchez N. Ahmad D.G. Romero, et al. 2004 Origin of aldosterone in the rat heart Endocrinology 145 4796 4802 10.1210/en.2004-0295 1:CAS:528:DC%2BD2cXptVyhtrk%3D 15308609 (Pubitemid 39551092)
5. J.S. Silvestre V. Robert C. Heymes, et al. 1998 Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation J Biol Chem 273 4883 4891 10.1074/jbc.273.9.4883 1:CAS:528:DyaK1cXhs1Cgtbw%3D 9478930 (Pubitemid 28108638)
6. J.M. Connell S.M. Mackenzie E.M. Freel, et al. 2008 A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function Endocr Rev 29 133 154 10.1210/er.2007-0030 1:CAS:528:DC%2BD1cXltlOhsr8%3D 18292466
7. R. Rocha C.T. Stier Jr I. Kifor, et al. 2000 Aldosterone: a mediator of myocardial necrosis and renal arteriopathy Endocrinology 141 3871 3878 10.1210/en.141.10.3871 1:CAS:528:DC%2BD3cXmvVGmtrk%3D 11014244
8. R. Rocha C.T. Stier Jr 2001 Pathophysiological effects of aldosterone in cardiovascular tissues Trends Endocrinol Metab 12 308 314 10.1016/S1043-2760(01) 00432-5 1:CAS:528:DC%2BD3MXlvFWltr0%3D 11504670
9. R. Rocha A.E. Rudolph G.E. Frierdich, et al. 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart Am J Physiol Heart Circ Physiol 283 H1802 H1810 1:CAS:528:DC%2BD38XovVOmt74%3D 12384457
10. Q. Wang E. Hummler J. Nussberger, et al. 2002 Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes J Am Soc Nephrol 13 1509 1516 10.1097/01.ASN.0000017902.77985.84 1:CAS:528:DC%2BD38XkvFels7w%3D 12039980 (Pubitemid 34579240)
11. K.T. Weber C.G. Brilla 1991 Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Circulation 83 1849 1865 1:STN:280:DyaK3M3kvFChtg%3D%3D 1828192
12. C.G. Brilla L.S. Matsubara K.T. Weber 1993 Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism J Mol Cell Cardiol 25 563 575 10.1006/jmcc.1993.1066 1:CAS:528:DyaK3sXlsFOgurw%3D 8377216 (Pubitemid 23208145)
13. E.R. Blasi R. Rocha A.E. Rudolph, et al. 2003 Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats Kidney Int 63 1791 1800 10.1046/j.1523-1755.2003.00929.x 1:CAS:528:DC%2BD3sXjslygsb4%3D 12675855 (Pubitemid 36513325)
14. M. Burnier O. Phan Q. Wang 2007 High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol Dial Transplant 22 2426 2429 10.1093/ndt/gfm321 17556416 (Pubitemid 47365499)
15. W.B. Lea E.S. Kwak J.M. Luther, et al. 2009 Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt Kidney Int 75 936 944 10.1038/ki.2009.9 1:CAS:528:DC%2BD1MXks1Sjs7o%3D 19225557
16. R.S. Vasan J.C. Evans M.G. Larson, et al. 2004 Serum aldosterone and the incidence of hypertension in nonhypertensive persons N Engl J Med 351 33 41 10.1056/NEJMoa033263 1:CAS:528:DC%2BD2cXltlOjsLY%3D 15229305 (Pubitemid 38857245)
17. S. Kathiresan M.G. Larson E.J. Benjamin, et al. 2005 Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study Am J Hypertens 18 657 665 10.1016/j.amjhyper.2004.12.005 1:CAS:528: DC%2BD2MXjvFelu7c%3D 15882548 (Pubitemid 40692433)
18. C.E. Grim A.W. Cowley Jr P. Hamet, et al. 2005 Hyperaldosteronism and hypertension: ethnic differences Hypertension 45 766 772 10.1161/01.HYP. 0000154364.00763.d5 1:CAS:528:DC%2BD2MXisV2jtbY%3D 15699471 (Pubitemid 40418379)
19. K. Swedberg P. Eneroth J. Kjekshus, et al. 1990 Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group Circulation 82 1730 1736 1:STN:280:DyaK3M%2FivF2juw%3D%3D 2225374
20. F. Beygui J.P. Collet J.J. Benoliel, et al. 2006 High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction Circulation 114 2604 2610 10.1161/CIRCULATIONAHA.106.634626 1:CAS:528:DC%2BD28Xht1Ohu7zJ 17116769 (Pubitemid 44967343)
21. B. Pitt F. Zannad W.J. Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D 10471456 (Pubitemid 29407370)
22. B. Pitt W. Remme F. Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 10.1056/NEJMoa030207 1:CAS:528:DC%2BD3sXis1ehurY%3D 12668699 (Pubitemid 36384098)
23. C.S. Fox M.G. Larson S.J. Hwang, et al. 2006 Cross-sectional relations of serum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample Kidney Int 69 2064 2069 10.1038/sj.ki.5000378 1:CAS:528:DC%2BD28XkvVyrsLc%3D 16572107 (Pubitemid 43924272)
24. G.P. Rossi L.A. Sechi G. Giacchetti, et al. 2008 Primary aldosteronism: cardiovascular, renal and metabolic implications Trends Endocrinol Metab 19 88 90 10.1016/j.tem.2008.01.006 1:CAS:528:DC%2BD1cXktV2iu7Y%3D 18314347
25. P. Milliez X. Girerd P.F. Plouin, et al. 2005 Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism J Am Coll Cardiol 45 1243 1248 10.1016/j.jacc.2005.01.015 1:CAS:528:DC%2BD2MXjtlagt70%3D 15837256 (Pubitemid 40523144)
26. C. Catena G. Colussi E. Nadalini, et al. 2008 Cardiovascular outcomes in patients with primary aldosteronism after treatment Arch Intern Med 168 80 85 10.1001/archinternmed.2007.33 1:CAS:528:DC%2BD1cXhslSntbs%3D 18195199
27. L.A. Sechi M. Novello R. Lapenna, et al. 2006 Long-term renal outcomes in patients with primary aldosteronism JAMA 295 2638 2645 10.1001/jama.295.22.2638 1:CAS:528:DC%2BD28XlvFWmtbo%3D 16772627 (Pubitemid 43882339)
28. M. Reincke L.C. Rump M. Quinkler, et al. 2009 Risk factors associated with a low glomerular filtration rate in primary aldosteronism J Clin Endocrinol Metabol 94 869 875 10.1210/jc.2008-1851 1:CAS:528:DC%2BD1MXjt1Wmtr0%3D
29. J.R. Sowers A. Whaley-Connell M. Epstein 2009 Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension Ann Intern Med 150 776 783 19487712
30. R. Yamashita T. Kikuchi Y. Mori, et al. 2004 Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade Endocr J 51 243 251 10.1507/endocrj.51.243 1:CAS:528:DC%2BD2cXmtFymt7o%3D 15118277 (Pubitemid 38657562)
31. C. Calle J. Campion M. Garcia-Arencibia, et al. 2003 Transcriptional inhibition of the human insulin receptor gene by aldosterone J Steroid Biochem Mol Biol 84 543 553 10.1016/S0960-0760(03)00072-4 1:CAS:528:DC%2BD3sXktFCqt7g%3D 12767279 (Pubitemid 36588808)
32. G. Giacchetti V. Ronconi F. Turchi, et al. 2007 Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study J Hypertens 25 177 186 10.1097/HJH.0b013e3280108e6f 1:CAS:528:DC%2BD28Xht1OhtrjK 17143190 (Pubitemid 44885680)
33. J. Widimsky Jr G. Sindelka T. Haas, et al. 2000 Impaired insulin action in primary hyperaldosteronism Physiol Res 49 241 244 1:CAS:528: DC%2BD3cXktVWgsLs%3D 10984090
34. B. Strauch J. Widimsky G. Sindelka, et al. 2003 Does the treatment of primary hyperaldosteronism influence glucose tolerance? Physiol Res 52 503 506 1:CAS:528:DC%2BD3sXnsFKjsLc%3D 12899664
35. J. Widimsky Jr B. Strauch G. Sindelka, et al. 2001 Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus? Physiol Res 50 603 607 11829322
36. G. Andronico S. Cottone M.T. Mangano, et al. 2001 Insulin, reninaldosterone system and blood pressure in obese people Int J Obes Relat Metab Disord 25 239 242 10.1038/sj.ijo.0801483 1:CAS:528:DC%2BD3MXhsFWqu78%3D 11410826
37. T.L. Goodfriend B. Egan K. Stepniakowski, et al. 1995 Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans Hypertension 25 30 36 1:CAS:528:DyaK2MXkvF2msb0%3D 7843750
38. S. Kidambi J.M. Kotchen C.E. Grim, et al. 2007 Association of adrenal steroids with hypertension and the metabolic syndrome in blacks Hypertension 49 704 711 10.1161/01.HYP.0000253258.36141.c7 1:CAS:528:DC%2BD2sXhslCmsbo%3D 17159085 (Pubitemid 46263216)
39. F. Fallo F. Veglio C. Bertello, et al. 2006 Prevalence and characteristics of the metabolic syndrome in primary aldosteronism J Clin Endocrinol Metabol 91 454 459 10.1210/jc.2005-1733 1:CAS:528: DC%2BD28XhsFKntLk%3D (Pubitemid 43236909)
40. T.L. Goodfriend B.M. Egan D.E. Kelley 1998 Aldosterone in obesity Endocrin Res 24 789 796 1:CAS:528:DyaK1MXlvVSgtw%3D%3D
41. T.L. Goodfriend D.L. Ball H.W. Gardner 2002 An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro Prostaglandins Leukot Essent Fatty Acids 67 163 167 10.1054/plef.2002.0414 1:CAS:528:DC%2BD38XnvFGrs7Y%3D 12324236 (Pubitemid 35052960)
42. B. Vogt M. Bochud M. Burnier 2007 The association of aldosterone with obesity-related hypertension and the metabolic syndrome Semin Nephrol 27 529 537 10.1016/j.semnephrol.2007.07.009 1:CAS:528:DC%2BD2sXhtFyjt7fN 17868790 (Pubitemid 47374907)
43. B.M. Egan K. Stepniakowski T.L. Goodfriend 1994 Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering Am J Hypertension 7 886 893 1:STN:280: DyaK2M7islWgtw%3D%3D
44. M. Bochud J. Nussberger P. Bovet, et al. 2006 Plasma aldosterone is independently associated with the metabolic syndrome Hypertension 48 239 245 10.1161/01.HYP.0000231338.41548.fc 1:CAS:528:DC%2BD28XmvFalurc%3D 16785327 (Pubitemid 44309818)
45. B.M. Egan V. Papademetriou M. Wofford, et al. 2005 Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure Am J Hypertension 18 3 12 10.1016/j.amjhyper.2004.08. 008 1:CAS:528:DC%2BD2MXit1Wmsrg%3D (Pubitemid 40187342)
46. J. Matrozova O. Steichen L. Amar, et al. 2009 Fasting glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study Hypertension 53 605 610 10.1161/HYPERTENSIONAHA.108.122002 1:CAS:528:DC%2BD1MXivVemtrw%3D 19221213
47. M.L. Tuck J. Sowers L. Dornfeld, et al. 1981 The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients N Engl J Med 304 930 933 1:CAS:528:DyaL3MXhslahu7g%3D 7010165
48. C. Dall'Asta P. Vedani P. Manunta, et al. 2009 Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity Nutr Metab Cardiovasc Dis 19 110 114 10.1016/j.numecd.2008.06.001 18718746
49. P.J. Barter M. Caulfield M. Eriksson, et al. 2007 Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2109 2122 10.1056/NEJMoa0706628 1:CAS:528:DC%2BD2sXhtlGns7bL 17984165 (Pubitemid 350146106)
50. M.J. Forrest D. Bloomfield R.J. Briscoe, et al. 2008 Torcetrapibinduced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br J Pharmacol 154 1465 1473 10.1038/bjp.2008.229 1:CAS:528:DC%2BD1cXptVajs7g%3D 18536749